drugset / Trial / NCT03097796
A Multiple Ascending Dose Study of PUL-042 in Stem Cell Transplant Recipients
Phase 1
Withdrawn
Pulmotect, Inc.
Cancer Prevention Research Institute of Texas · collabNational Heart, Lung, and Blood Institute (NHLBI) · collab
NaSingle-groupOpen-labelPrevention
Summary
Subjects with hematologic malignancies or recipients of a first allogenic or autologus hematopoietic stem cell transplant, without any evidence or respiratory infection, will receive 4 doses of PUL-042 Inhalation Solution over a 2 week period. Subjects will be evaluated for tolerability of the drug. If tolerated, dose escalation may occur with up to 4 dose levels tested
Timeline
- Start
- 2024-12
- Primary completion
- 2026-03
- Completion
- 2026-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | PUL-042 | Oligonucleotide (other) | — | Inhaled |